Healthcare Industry News: Titan Spine
News Release - October 20, 2016
Titan Spine Expands Sales Force to Meet Growing Demand, Support Recent Full Launch of its New nanoLOCK(R) Surface TechnologyMEQUON, Wis.--(Healthcare Sales & Marketing Network)--Titan Spine, a medical device surface technology company focused on developing innovative spinal interbody fusion implants, today announced that it has doubled its sales management team with the addition of nine new members to meet the growing demand for its Endoskeleton® line of titanium interbody fusion devices and to support the recent full launch of its next-generation nanoLOCK® surface technology.
Steve Cichy, Vice President of Sales for Titan Spine, commented, “The addition of nine new sales managers, all of which bring a tremendous amount of spine sales experience and success, was required to meet accelerating demand for our surface technology offerings. They will play a critical role in working closely with our distribution network partners across the United States to further drive surgeon adoption, to support the recent full launch of nanoLOCK®, and to capitalize on the dramatically increased access to surgeons and hospital systems our recently-awarded Section X new technology code from CMS affords us. Our sales expansion initiative is ongoing and is made possible, in large part, from proceeds from our recent substantial round of financing with investor Southlake Equity Group.”
Titan Spine offers a full line of Endoskeleton® devices that feature Titan Spine’s proprietary nanoLOCK® surface technology, consisting of a unique combination of roughened topographies at the macro, micro, and nano levels (MMN™). This unique combination of surface topographies is designed to create an optimal host-bone response and actively participate in the fusion process by promoting the upregulation of osteogenic and angiogenic factors necessary for bone growth, encouraging natural production of bone morphogenetic proteins (BMPs), downregulating inflammatory factors, and creating the potential for a faster and more robust fusion.1,2 All Endoskeleton® devices are covered by the company’s risk share warranty.
About Titan Spine
Titan Spine, LLC is a surface technology company focused on the design and manufacture of interbody fusion devices for the spine. The company is committed to advancing the science of surface engineering to enhance the treatment of various pathologies of the spine that require fusion. Titan Spine, located in Mequon, Wisconsin and Laichingen, Germany, markets a full line of Endoskeleton® interbody devices featuring its proprietary roughened surfaces in the U.S. and portions of Europe through its sales force and a network of independent distributors. To learn more, visit www.titanspine.com.
1 Olivares-Navarrete, R., Hyzy S.L., Gittens, R.A., Berg, M.E., Schneider, J.M., Hotchkiss, K., Schwartz, Z., Boyan, B. D. Osteoblast lineage cells can discriminate microscale topographic features on titanium-aluminum-vanadium surfaces. Ann Biomed Eng. 2014 Dec; 42 (12): 2551-61.
2 Olivares-Navarrete, R., Hyzy, S.L., Slosar, P.J., Schneider, J.M., Schwartz, Z., and Boyan, B.D. (2015). Implant materials generate different peri-implant inflammatory factors: PEEK promotes fibrosis and micro-textured titanium promotes osteogenic factors. Spine, Volume 40, Issue 6, 399–404.
Source: Titan Spine
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.